CD8A and neoplasm: Experimental results demonstrated that the DPPA-TRPP/Tab nanoplatform not only increased tumor accumulation but also suppressed CAF formation (Fig. 9C) and enhanced the activation of CD4+ and CD8+ T cells (Fig. 9B).